Key insights
- Wells Fargo has named Annexon, Inc. (ANNX) its top pick in biotechnology, maintaining an Overweight rating and a $27 price target. The firm highlights a compelling setup for ANNX heading into a critical Q4 2026 data readout for its ARCHER II trial in generalized myasthenia gravis. Wells Fargo assigns a 55% probability of success for a positive Month-15 outcome, with potential for significant stock re-rating. The company's Biologics License Application submission is also on track for Q4 2026.
Investing.com -- Wells Fargo has identified Annexon, Inc. as its top pick in the biotechnology sector, maintaining an Overweight rating with a price target of $27.00. The firm highlighted the company's compelling setup heading into a critical fourth-quarter 2026 data readout.
The investment firm's analysis centers on Annexon's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA). Wells Fargo assigns a 55% probability of success for a positive Month-15 outcome, with potential for a three-to-four times stock re-rating. The firm noted that even a "continue" decision would preserve the Month-24 readout in third-quarter 2027 as a second opportunity, creating what it describes as an attractive asymmetric setup.
Wells Fargo's top biotechnology pick features multiple near-term catalysts. The ARCHER II trial's fourth-quarter 2026 readout represents the key binary event, with a Data Monitoring Committee making a decision at Month 15. Wells Fargo's statistical analysis suggests a modest efficacy bar of approximately 5.0% to 6.6% sham-adjusted delta, compared to 14.2% achieved in Phase 2 trials.
The company's tanruprubart Biologics License Application remains on track for fourth-quarter 2026 submission. Management is finalizing the U.S. regulatory package with approximately 18 FORWARD patients and indicated that European Medicines Agency feedback has helped shape the FDA filing. A Day 180 regulatory call raised no issues, and a first-half 2027 European Union decision remains on schedule. Annexon ended third-quarter 2026 with approximately $213 million in cash.
The company secured an up-to-$200 million credit facility with Oxford Finance in August, drawing $50 million at closing. Management reiterated financial runway into 2028, which Wells Fargo views as sufficient to fund operations through the GA readout and near-term regulatory milestones. Shares are down 16% year-to-date versus the SPDR S&P Biotech ETF's 29% gain.
Wells Fargo attributes this underperformance to caution around the upcoming Data Monitoring Committee decision, expected between Thanksgiving and Christmas.
Original Article